Abstract:Deregulation of long non-coding RNAs (lncRNAs) is a common feature of cancer, including Multiple Myeloma (MM). In our previous studies, we detected 11,495 and 40,511 previously non-annotated lncRNAs during normal humoral immune response and MM patient samples, respectively. These results support an important role for the lncRNAs transcriptome in this hematological malignancy. lncRNAs are genes that differ from coding genes in that they do not give rise to a protein. Nevertheless, lncRNA could undergo the same genetic alterations as coding genes. In this study, we hypothesize that lncRNAs can be involved in the principal genetic alterations occurring in MM such as chromosomal translocations, affecting the Immunoglobulin loci (IG) and in the majority of which the fusion partner still remains unknown. In order to unveil the role of lncRNAs in fusion transcripts occurring in MM, we analyzed the strand specific RNA-seq (ssRNA-seq) data obtained from 35 samples from different subpopulations of B cells (Naïve, Centroblast, Centrocyte, Memory and Plasma cells (PCs)), purified PCs from 32 MM patients and 3 MM cell lines. Chimeric transcripts were detected with the STAR-Fusion software, identifying 1,347 novel fusion transcripts ranging from 1 to 142 chimeric transcripts per sample. Strikingly, healthy PC samples (from tonsils and bone marrow) yielded the highest number of fusion transcripts, while other B cell subpopulations showed overall low numbers and MM samples turned out highly variable. 96% of all fusion transcripts detected in healthy PCs occurred with IG genes and harbored few reads per transcript, suggesting that the hyperactive transcription of the IG loci in PCs may be the cause for their formation and are probably not involved in the pathogenesis of the disease. We also found that HLA fusion transcripts were abundant in Naïve B cells, disappearing progressively during the humoral immune response (Figure 1). Interestingly, fusion transcripts identified in different B cell subpopulations were not detected in MM samples. Next, we focus on myeloma samples and identified 362 chimeric transcripts (312 unique) expressed specifically in MM (ranging from 2 to 24 chimeric transcripts per sample), most of them (84%) identified for the first time. 69% of these transcripts partnered with the IG genes, while the other fusions involved two non-IG genes. Interestingly, as we hypothesized, 26,5% of the chimeric transcripts in MM occurred with lncRNA as a partner, increasing the relevance of lncRNAs in this disease. Furthermore, using the read distribution per chimeric transcript, we identified a prevalent reciprocal transcript or a prevalent transcript expressed with >1 FFPM in 47% of MM samples, suggesting that they could derived from underlying genomic rearrangements. Besides these prevalent transcripts, we observed that 40% of the non-IG fusion transcripts occurred between adjacent genes, defining novel MM-transcriptional read-throughs, possibly caused by the oncogenic stress suffered by MM cells. Some of these chimeric transcripts were validated in different cell lines of MM by conventional PCR and sequencing. In summary, our findings show that ssRNA-seq data is an adequate strategy for the detection of chimeric transcripts in MM, being able to detect highly expressed chimeric transcripts that probably were derived from an underlying genomic rearrangements and also new categories of chimeric transcripts. In addition, our study reveals a complex landscape of fusion transcripts in the MM, many of them including a lncRNA, which could be potential therapeutic targets for the development of new treatment strategies for MM. Disclosures Paiva: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Merck, Novartis, Roche, and Sanofi; unrestricted grants from Celgene, EngMab, Sanofi, and Takeda; and consultancy for Celgene, Janssen, and Sanofi: Consultancy, Honoraria, Research Funding, Speakers Bureau. San-Miguel:Amgen, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, Roche, Sanofi, and Takeda: Consultancy, Honoraria.

Effective requesting method to detect fusion transcripts in chronic myelomonocytic leukemia RNA-seq

Tailored Digital PCR Follow-Up of Rare Fusion Transcripts after Initial Detection through RNA Sequencing in Hematological Malignancies

Fusion Gene Detection and Quantification by Asymmetric Capture Sequencing (aCAP-Seq)

Detection of Cryptic Gene Fusion and Chimeric RNA Variants in Relapsed/Refractory Acute Myeloid Leukemia Patients Diagnosed with KMT2A/Afdn Chromosomal Translocation

The Use of Targeted RNA- Sequencing Assay in the Diagnostic Evaluation of Acute Myeloid Leukaemia(AML)

PS1040 DETECTION OF MRD MAY PREDICT THE OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH BIALLELIC CEBPA MUTATIONS

Detection of leukemia gene fusions by targeted RNA-sequencing in routine diagnostics

Panel-based RNA fusion sequencing improves diagnostics of pediatric acute myeloid leukemia

Detection of Hybrid Fusion Transcripts, Aberrant Transcript Expression, and Specific Single Nucleotide Variants in Acute Leukemia and Myeloid Disorders with Recurrent Gene Rearrangements

1148P Identification and Validation of RET Fusions in Lung Adenocarcinoma Through DNA and RNA Sequencing

Lncrnas As New Partners of Novel Chimeric Transcripts in Multiple Myeloma

The Fusion of CLEC12A and MIR223HG Arises from a trans-Splicing Event in Normal and Transformed Human Cells

Mutational profiling in acute lymphoblastic leukemia by RNA sequencing and chromosomal genomic array testing

Transcriptome Sequencing to Detect Gene Fusions in Cancer

The application of targeted RNA sequencing for the analysis of fusion genes, gene mutations, IKZF1 intragenic deletion, and CRLF2 overexpression in acute lymphoblastic leukemia

SeekFusion - A Clinically Validated Fusion Transcript Detection Pipeline for PCR-Based Next-Generation Sequencing of RNA

Recurrent and novel fusions detected by targeted RNA sequencing as part of the diagnostic workflow of soft tissue and bone tumours

Cicero: An Accurate Method For Detecting Complex And Diverse Driver Fusions Using Cancer Transcriptome Sequencing (Rna-Seq) Data

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

Comprehensive Molecular Profiling of NPM1-Mutated Acute Myeloid Leukemia Using RNAseq Approach

Abstract 5174: Utilization of Cell free messenger RNA Sequencing for non-invasive molecular profiling of multiple myeloma and Acute Myeloid Leukemia